Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease

Lee-Way Jin, Jacopo Di Lucente, Hai M. Nguyen, Vikrant Singh, Latika Singh, Monique Chavez, Trevor Bushong, Heike Wulff, Izumi Maezawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Microglia play a pivotal role in the initiation and progression of Alzheimer's disease (AD). We here tested the therapeutic hypothesis that the Ca 2+ -activated potassium channel KCa3.1 constitutes a potential target for treating AD by reducing neuroinflammation. Methods: To determine if KCa3.1 is relevant to AD, we tested if treating cultured microglia or hippocampal slices with Aβ oligomer (AβO) activated KCa3.1 in microglia, and if microglial KCa3.1 was upregulated in 5xFAD mice and in human AD brains. The expression/activity of KCa3.1 was examined by qPCR, Western blotting, immunohistochemistry, and whole-cell patch-clamp. To investigate the role of KCa3.1 in AD pathology, we resynthesized senicapoc, a clinically tested KCa3.1 blocker, and determined its pharmacokinetic properties and its effect on microglial activation, Aβ deposition and hippocampal long-term potentiation (hLTP) in 5xFAD mice. Results: We found markedly enhanced microglial KCa3.1 expression/activity in brains of both 5xFAD mice and AD patients. In hippocampal slices, microglial KCa3.1 expression/activity was increased by AβO treatment, and its inhibition diminished the proinflammatory and hLTP-impairing activities of AβO. Senicapoc exhibited excellent brain penetrance and oral availability, and in 5xFAD mice, reduced neuroinflammation, decreased cerebral amyloid load, and enhanced hippocampal neuronal plasticity. Interpretation: Our results prompt us to propose repurposing senicapoc for AD clinical trials, as senicapoc has excellent pharmacological properties and was safe and well-tolerated in a prior phase-3 clinical trial for sickle cell anemia. Such repurposing has the potential to expedite the urgently needed new drug discovery for AD.

Original languageEnglish (US)
Pages (from-to)723-738
Number of pages16
JournalAnnals of Clinical and Translational Neurology
Volume6
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Alzheimer Disease
Microglia
Long-Term Potentiation
Brain
Phase III Clinical Trials
Neuronal Plasticity
senicapoc
Penetrance
Potassium Channels
Sickle Cell Anemia
Drug Discovery
Amyloid
Pharmacokinetics
Western Blotting
Immunohistochemistry
Clinical Trials
Pharmacology
Pathology
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease. / Jin, Lee-Way; Lucente, Jacopo Di; Nguyen, Hai M.; Singh, Vikrant; Singh, Latika; Chavez, Monique; Bushong, Trevor; Wulff, Heike; Maezawa, Izumi.

In: Annals of Clinical and Translational Neurology, Vol. 6, No. 4, 01.04.2019, p. 723-738.

Research output: Contribution to journalArticle

Jin, Lee-Way ; Lucente, Jacopo Di ; Nguyen, Hai M. ; Singh, Vikrant ; Singh, Latika ; Chavez, Monique ; Bushong, Trevor ; Wulff, Heike ; Maezawa, Izumi. / Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease. In: Annals of Clinical and Translational Neurology. 2019 ; Vol. 6, No. 4. pp. 723-738.
@article{5f60d789d4e84beeb9f04633dc28eef9,
title = "Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease",
abstract = "Objective: Microglia play a pivotal role in the initiation and progression of Alzheimer's disease (AD). We here tested the therapeutic hypothesis that the Ca 2+ -activated potassium channel KCa3.1 constitutes a potential target for treating AD by reducing neuroinflammation. Methods: To determine if KCa3.1 is relevant to AD, we tested if treating cultured microglia or hippocampal slices with Aβ oligomer (AβO) activated KCa3.1 in microglia, and if microglial KCa3.1 was upregulated in 5xFAD mice and in human AD brains. The expression/activity of KCa3.1 was examined by qPCR, Western blotting, immunohistochemistry, and whole-cell patch-clamp. To investigate the role of KCa3.1 in AD pathology, we resynthesized senicapoc, a clinically tested KCa3.1 blocker, and determined its pharmacokinetic properties and its effect on microglial activation, Aβ deposition and hippocampal long-term potentiation (hLTP) in 5xFAD mice. Results: We found markedly enhanced microglial KCa3.1 expression/activity in brains of both 5xFAD mice and AD patients. In hippocampal slices, microglial KCa3.1 expression/activity was increased by AβO treatment, and its inhibition diminished the proinflammatory and hLTP-impairing activities of AβO. Senicapoc exhibited excellent brain penetrance and oral availability, and in 5xFAD mice, reduced neuroinflammation, decreased cerebral amyloid load, and enhanced hippocampal neuronal plasticity. Interpretation: Our results prompt us to propose repurposing senicapoc for AD clinical trials, as senicapoc has excellent pharmacological properties and was safe and well-tolerated in a prior phase-3 clinical trial for sickle cell anemia. Such repurposing has the potential to expedite the urgently needed new drug discovery for AD.",
author = "Lee-Way Jin and Lucente, {Jacopo Di} and Nguyen, {Hai M.} and Vikrant Singh and Latika Singh and Monique Chavez and Trevor Bushong and Heike Wulff and Izumi Maezawa",
year = "2019",
month = "4",
day = "1",
doi = "10.1002/acn3.754",
language = "English (US)",
volume = "6",
pages = "723--738",
journal = "Annals of Clinical and Translational Neurology",
issn = "2328-9503",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease

AU - Jin, Lee-Way

AU - Lucente, Jacopo Di

AU - Nguyen, Hai M.

AU - Singh, Vikrant

AU - Singh, Latika

AU - Chavez, Monique

AU - Bushong, Trevor

AU - Wulff, Heike

AU - Maezawa, Izumi

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Objective: Microglia play a pivotal role in the initiation and progression of Alzheimer's disease (AD). We here tested the therapeutic hypothesis that the Ca 2+ -activated potassium channel KCa3.1 constitutes a potential target for treating AD by reducing neuroinflammation. Methods: To determine if KCa3.1 is relevant to AD, we tested if treating cultured microglia or hippocampal slices with Aβ oligomer (AβO) activated KCa3.1 in microglia, and if microglial KCa3.1 was upregulated in 5xFAD mice and in human AD brains. The expression/activity of KCa3.1 was examined by qPCR, Western blotting, immunohistochemistry, and whole-cell patch-clamp. To investigate the role of KCa3.1 in AD pathology, we resynthesized senicapoc, a clinically tested KCa3.1 blocker, and determined its pharmacokinetic properties and its effect on microglial activation, Aβ deposition and hippocampal long-term potentiation (hLTP) in 5xFAD mice. Results: We found markedly enhanced microglial KCa3.1 expression/activity in brains of both 5xFAD mice and AD patients. In hippocampal slices, microglial KCa3.1 expression/activity was increased by AβO treatment, and its inhibition diminished the proinflammatory and hLTP-impairing activities of AβO. Senicapoc exhibited excellent brain penetrance and oral availability, and in 5xFAD mice, reduced neuroinflammation, decreased cerebral amyloid load, and enhanced hippocampal neuronal plasticity. Interpretation: Our results prompt us to propose repurposing senicapoc for AD clinical trials, as senicapoc has excellent pharmacological properties and was safe and well-tolerated in a prior phase-3 clinical trial for sickle cell anemia. Such repurposing has the potential to expedite the urgently needed new drug discovery for AD.

AB - Objective: Microglia play a pivotal role in the initiation and progression of Alzheimer's disease (AD). We here tested the therapeutic hypothesis that the Ca 2+ -activated potassium channel KCa3.1 constitutes a potential target for treating AD by reducing neuroinflammation. Methods: To determine if KCa3.1 is relevant to AD, we tested if treating cultured microglia or hippocampal slices with Aβ oligomer (AβO) activated KCa3.1 in microglia, and if microglial KCa3.1 was upregulated in 5xFAD mice and in human AD brains. The expression/activity of KCa3.1 was examined by qPCR, Western blotting, immunohistochemistry, and whole-cell patch-clamp. To investigate the role of KCa3.1 in AD pathology, we resynthesized senicapoc, a clinically tested KCa3.1 blocker, and determined its pharmacokinetic properties and its effect on microglial activation, Aβ deposition and hippocampal long-term potentiation (hLTP) in 5xFAD mice. Results: We found markedly enhanced microglial KCa3.1 expression/activity in brains of both 5xFAD mice and AD patients. In hippocampal slices, microglial KCa3.1 expression/activity was increased by AβO treatment, and its inhibition diminished the proinflammatory and hLTP-impairing activities of AβO. Senicapoc exhibited excellent brain penetrance and oral availability, and in 5xFAD mice, reduced neuroinflammation, decreased cerebral amyloid load, and enhanced hippocampal neuronal plasticity. Interpretation: Our results prompt us to propose repurposing senicapoc for AD clinical trials, as senicapoc has excellent pharmacological properties and was safe and well-tolerated in a prior phase-3 clinical trial for sickle cell anemia. Such repurposing has the potential to expedite the urgently needed new drug discovery for AD.

UR - http://www.scopus.com/inward/record.url?scp=85064504008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064504008&partnerID=8YFLogxK

U2 - 10.1002/acn3.754

DO - 10.1002/acn3.754

M3 - Article

AN - SCOPUS:85064504008

VL - 6

SP - 723

EP - 738

JO - Annals of Clinical and Translational Neurology

JF - Annals of Clinical and Translational Neurology

SN - 2328-9503

IS - 4

ER -